Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of “Moderate Buy” by Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $46.6667.

AVTX has been the subject of several recent research reports. Bank of America initiated coverage on Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Wedbush lowered their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Citizens Jmp lowered their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Finally, Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of the company’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares of the company’s stock, valued at $116,239.20. This represents a 48.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $65,232.22. The trade was a 52.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 112,586 shares of company stock valued at $2,089,651 in the last ninety days. Insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC boosted its position in Avalo Therapeutics by 39.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after buying an additional 382,300 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after purchasing an additional 289,786 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after purchasing an additional 240,000 shares during the last quarter. Caligan Partners LP lifted its position in shares of Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after purchasing an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of Avalo Therapeutics during the third quarter worth about $10,390,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Stock Up 7.5%

AVTX stock opened at $15.40 on Thursday. The company has a market cap of $809.58 million, a price-to-earnings ratio of -2.82 and a beta of 0.83. The business has a fifty day simple moving average of $15.53 and a 200-day simple moving average of $16.12. Avalo Therapeutics has a 52 week low of $4.47 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. As a group, analysts expect that Avalo Therapeutics will post -2.58 earnings per share for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.